dipyridamole has been researched along with Rheumatoid Arthritis in 9 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dipyridamole inhibits the cellular uptake and metabolism of adenosine and we have, therefore, examined the effects of dipyridamole in patients with rheumatoid arthritis in an attempt to alleviate their symptoms." | 9.12 | Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole. ( Darlington, LG; Forrest, CM; Harman, G; Mackay, GM; Oxford, L; Stone, TW; Stoy, N, 2006) |
| " Since the vascular protective drug dipyridamole inhibits the uptake and metabolism of adenosine we have now tested this compound in patients with rheumatoid arthritis to assess its effects on their symptoms." | 9.12 | Purine metabolism and clinical status of patients with rheumatoid arthritis treated with dipyridamole. ( Darlington, LG; Forrest, CM; Harman, G; Mackay, GM; Oxford, L; Stone, TW; Stoy, N, 2006) |
| "Dipyridamole Thallium-201 (T1) scintigraphic studies to evaluate microcirculation of the heart were performed in 54 patients with rheumatoid arthritis (RA) who had neither cardiac complaints nor myocardial damages on ECG." | 7.69 | [Detection of myocardial lesions by dipyridamole thallium-201 scintigraphy in patients with rheumatoid arthritis]. ( Momose, S, 1995) |
| "To assess red blood cell deformability (RCD) in patients with rheumatoid arthritis (RA) without extraarticular manifestations and in RA with vasculitic complications (RV), and to assess whether in vitro dipyridamole improves RCD." | 7.69 | Reduced red blood cell deformability in patients with rheumatoid vasculitis. Improvement after in vitro treatment with dipyridamole. ( Belch, JJ; Lau, CS; Saniabadi, AR, 1995) |
| " Dipyridamole inhibits the cellular uptake and metabolism of adenosine and we have, therefore, examined the effects of dipyridamole in patients with rheumatoid arthritis in an attempt to alleviate their symptoms." | 5.12 | Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole. ( Darlington, LG; Forrest, CM; Harman, G; Mackay, GM; Oxford, L; Stone, TW; Stoy, N, 2006) |
| " Since the vascular protective drug dipyridamole inhibits the uptake and metabolism of adenosine we have now tested this compound in patients with rheumatoid arthritis to assess its effects on their symptoms." | 5.12 | Purine metabolism and clinical status of patients with rheumatoid arthritis treated with dipyridamole. ( Darlington, LG; Forrest, CM; Harman, G; Mackay, GM; Oxford, L; Stone, TW; Stoy, N, 2006) |
| "Dipyridamole Thallium-201 (T1) scintigraphic studies to evaluate microcirculation of the heart were performed in 54 patients with rheumatoid arthritis (RA) who had neither cardiac complaints nor myocardial damages on ECG." | 3.69 | [Detection of myocardial lesions by dipyridamole thallium-201 scintigraphy in patients with rheumatoid arthritis]. ( Momose, S, 1995) |
| "To assess red blood cell deformability (RCD) in patients with rheumatoid arthritis (RA) without extraarticular manifestations and in RA with vasculitic complications (RV), and to assess whether in vitro dipyridamole improves RCD." | 3.69 | Reduced red blood cell deformability in patients with rheumatoid vasculitis. Improvement after in vitro treatment with dipyridamole. ( Belch, JJ; Lau, CS; Saniabadi, AR, 1995) |
| " There seems to be a boost and extension of the glucocorticoid effect by the combination, without a clear increase of adverse effects, potentially allowing the application of lower dosages." | 1.35 | Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids: another promise? ( Bijlsma, JW; Jacobs, JW, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobs, JW | 1 |
| Bijlsma, JW | 1 |
| Turiel, M | 1 |
| Atzeni, F | 1 |
| Tomasoni, L | 1 |
| de Portu, S | 1 |
| Delfino, L | 1 |
| Bodini, BD | 1 |
| Longhi, M | 1 |
| Sitia, S | 1 |
| Bianchi, M | 1 |
| Ferrario, P | 1 |
| Doria, A | 1 |
| De Gennaro Colonna, V | 1 |
| Sarzi-Puttini, P | 1 |
| Riksen, NP | 1 |
| Barrera, P | 1 |
| van den Broek, PH | 1 |
| van Riel, PL | 1 |
| Smits, P | 1 |
| Rongen, GA | 1 |
| Forrest, CM | 2 |
| Stoy, N | 2 |
| Stone, TW | 2 |
| Harman, G | 2 |
| Mackay, GM | 2 |
| Oxford, L | 2 |
| Darlington, LG | 2 |
| Momose, S | 1 |
| Lau, CS | 1 |
| Saniabadi, AR | 1 |
| Belch, JJ | 1 |
| Baron, BW | 1 |
| Martin, MS | 1 |
| Sucharetza, BS | 1 |
| Jeon, H | 1 |
| Baron, JM | 1 |
| Vogel, G | 1 |
| Krusch, G | 1 |
1 review available for dipyridamole and Rheumatoid Arthritis
| Article | Year |
|---|---|
Four patients with both thrombotic thrombocytopenic purpura and autoimmune thrombocytopenic purpura: the concept of a mixed immune thrombocytopenia syndrome and indications for plasma exchange.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Autoimmune Diseases; Blood Platelets; Combined Modality Thera | 2001 |
2 trials available for dipyridamole and Rheumatoid Arthritis
| Article | Year |
|---|---|
Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole.
Topics: Adenosine; Adolescent; Adult; Aged; Arthritis, Rheumatoid; Cytokines; Dipyridamole; Dose-Response Re | 2006 |
Purine metabolism and clinical status of patients with rheumatoid arthritis treated with dipyridamole.
Topics: Adenosine; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chromatography, | 2006 |
6 other studies available for dipyridamole and Rheumatoid Arthritis
| Article | Year |
|---|---|
Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids: another promise?
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Dipyridamole; Drug Therapy, Combination; Gluco | 2009 |
Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients.
Topics: Adult; Aged; Arginine; Arthritis, Rheumatoid; Biomarkers; Carotid Artery, Common; Case-Control Studi | 2009 |
Methotrexate modulates the kinetics of adenosine in humans in vivo.
Topics: Adenosine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Adult; Aged; Antirheumatic Agents; A | 2006 |
[Detection of myocardial lesions by dipyridamole thallium-201 scintigraphy in patients with rheumatoid arthritis].
Topics: Aged; Arthritis, Rheumatoid; Cardiomyopathies; Dipyridamole; Female; Heart; Humans; Male; Middle Age | 1995 |
Reduced red blood cell deformability in patients with rheumatoid vasculitis. Improvement after in vitro treatment with dipyridamole.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dipyridamole; Erythrocyte Deformability; Female; Filtration; Hum | 1995 |
[The effect of various drugs in clinical use on thrombocyte functions].
Topics: Adolescent; Adult; Aged; Aminobenzoates; Aminocaproates; Arthritis, Rheumatoid; Aspirin; Blood Coagu | 1969 |